Japan In-Vitro Diagnostics Market Analysis Report 2024-2030: Strategic Partnerships Drive Innovations, Tumor Marker Testing Gains Momentum

News provided by

Mar 11, 2024, 22:30 ET

DUBLIN, March 11, 2024 /PRNewswire/ -- The "Japan In-Vitro Diagnostics Market (by Segment and Company), Size, Share, Major Deals, Trends, Company Analysis and Recent Developments - Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Japan's in-vitro diagnostics market is predicted to reach US$ 6.62 Billion by 2030, from US$ 4.59 Billion in 2023

Japan is one of the leading in-vitro diagnostics markets in the Asia-Pacific region. In-vitro diagnostics refers to the diagnosis of disease or other conditions of the human body through the collection, preparation, and testing of human samples with reagents, instruments, and systems.

Japan is facing the challenges of fighting infectious diseases including HBV, TB, HCV, and HIV, as well as various chronic diseases and cancer. The population of Japan is aging rapidly. For instance, as of September 2023, close to 36.23 million people in Japan were estimated to be within the age group of 65 and over.

Japan's quickly aging population leads to an explosion of chronic conditions such as heart disease and cancer. All of these conditions can be diagnosed and monitored using IVD products. However, some of the factors limiting the growth of the market are a lack of proper reimbursement policies and a stringent regulatory framework.

Japan In-Vitro Diagnostics (IVD) Market - Recent Developments

In January 2024, bioMerieux announced the acquisition of LUMED, a software company that has developed a clinical decision support system to help hospitals optimize antimicrobial prescriptions and monitor healthcare-associated infections.
In August 2023, Sysmex Corporation announced an expansion of the Global Business Partnership Agreement (GBPA) with Roche Diagnostics International Ltd.
In April 2023, Oxford Nanopore Technologies plc, and bioMerieux SA teamed up to improve health outcomes globally by exploring selected opportunities to bring nanopore sequencing to the infectious disease diagnostics market.
In October 2023, Sysmex and Fujirebio entered into a business collaboration agreement in the field of immunoassay, in a bid to promote cooperation to accelerate their global expansion, and to contribute to the development and advancement of immunoassay.
In December 2022, bioMerieux announced the CE-marking of VIDAS KUBE, the next-generation automated immunoassay system for the VIDAS range.

By Segment: Japan IVD Market and Forecast - Key Takeaways

On a segment basis, immunology and genetic testing are the leading segments of the Japan IVD market.
Genetic Testing is the fastest-growing segment of the Japanese in-vitro diagnostics market.
Tumor Marker and Hematology segments are competing closely with each other to grab the maximum share of the pie.
The growth of the hematology market is attributed to factors such as the increasing incidences of blood disorders, the growing adoption of automated hematology instruments by diagnostic laboratories, the emergence of high throughput hematology analyzers, and the introduction of technologically advanced hematology instruments.
Microbiology testing is witnessing growth due to technological advancements and increasing infectious disease incidences.

Japan IVD Market - Company Analysis

In the Japan IVD market, Roche Diagnostics and Sysmex Corporation are the leading players.
Thermo Fisher Scientific Inc., Danaher Corporation, Abbott Laboratories, and Biomerieux are the other top four players in the Japan IVD market.
In the diagnostics business, Abbott will focus on driving sales growth from its Alinity suite of diagnostics instruments and its portfolio of rapid diagnostic testing systems.
In August 2023, Sysmex Corporation announced an expansion of the Global Business Partnership Agreement (GBPA) with Roche Diagnostics International Ltd.
In April 2023, bioMerieux submitted a 510(k) premarket notification to the U.S. FDA for the VITEK REVEAL, formerly known as SPECIFIC REVEAL Rapid AST System.
In October 2023, Sysmex and Fujirebio entered into a business collaboration agreement in the field of immunoassay, in a bid to promote cooperation to accelerate their global expansion, and to contribute to the development and advancement of immunoassay.

Key Topics Covered:

1. Executive Summary

2. Japan In-Vitro Diagnostics (IVD) Market and Market Share Analysis - Forecast to 2030
2.1 Japan IVD Market and Forecast (2008 - 2030)
2.2 By Segment - Japan IVD Market Share and Forecast (2008 - 2030)
2.3 By Company - Japan IVD Share and Forecast (2015 - 2030)

3. Japan IVD - Segments Wise Market and Forecast (2008 - 2030)
3.1 Urine & Feces Market and Forecast
3.2 Hematology Market and Forecast
3.3 Clinical Chemistry Market and Forecast
3.4 SMBG Market and Forecast
3.5 Tumor Marker Market and Forecast
3.6 Immunoassay Market and Forecast
3.7 Infectious Disease Market and Forecast
3.8 Microbiology Market and Forecast
3.9 Pathology Market and Forecast
3.10 Genetic Testing Market and Forecast
3.11 Others Market and Forecast

4. Japan IVD Market - Company Analysis (2014 - 2030)
4.1 Roche Diagnostics
4.1.1 Company Overview
4.1.2 Roche Diagnostics - Japan IVD Sales and Forecast
4.1.3 Recent Developments
4.2 Abbott Laboratories
4.3 Danaher Corporation
4.4 bioMerieux S.A.
4.5 Sysmex Corporation
4.6 Bio-Rad Laboratories, Inc.
4.7 Becton Dickinson and Company
4.8 Thermo Fisher Scientific Inc.
4.9 Others - Japan IVD Sales and Forecast

5. In-Vitro Diagnostics (IVD) Market - Major Deals

6. In-Vitro Diagnostics (IVD) Market - Recent Developments

7. Japan In-Vitro Diagnostics - Market Dynamics
7.1 Japan IVD Market - Driving Factors
7.2 Japan IVD Market - Challenges

For more information about this report visit https://www.researchandmarkets.com/r/6tajor

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets